Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Promising preliminary results obtained with Melacine/Intron A combination in stage IV melanoma

March 27, 1998

Cytogen halts autologous lymphocyte therapy program

March 27, 1998

Coulter completes patient enrollment in Bexxar phase III trial

March 25, 1998

Phase II ImmTher trial begins in pediatric cancer patients

March 19, 1998

Cel-Sci expands North American clinical trial for Multikine

March 18, 1998

Ribi ImmunoChem and Schering-Plough sign distribution agreement for Melacine

March 18, 1998

Techniclone to begin TNT clinical trials using unique delivery system

March 16, 1998

Genentech and DAKO establish development agreement for HER2 detection

March 13, 1998

Patient enrollment completed for phase I/II pancreatic cancer trial

March 13, 1998

Avicidin advances to phase II

March 5, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 24, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
In the clinic for June 22, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...
K2 nabs two Antengene bispecific TCEs in $2B license, option deal
BioWorld
MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene...